Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of trilaciclib (trachloril) for bone marrow protection and efficacy in ES-SCLC chemotherapy
ChiCTR2300070061Phase 4Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Incidence of severe neutropenia (SN). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300070061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070061.